Power Law company profile

Immunovant’s

Biotech & Life Sciences · New York City, United States · Founded 2018 · IPO 2019 Unicorn

Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions

Valuation

$4.81B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

4 investors on Immunovant’s's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

HanAll Biopharma

RTW Investments

BVF Partners

Roivant Sciences

Global footprint

Where Immunovant’s has talent and traffic

Workforce by country

🇺🇸 United States · New York City HQ

Book a demo for the full country breakdown

Web traffic by country

6.7K monthly visits
across markets

🇺🇸 United States73.1%

🇮🇳 India16.4%

🇬🇧 United Kingdom7.5%

🇨🇦 Canada1.5%

🇧🇪 Belgium1.5%

Top 5 markets shown

Market sentiment

What the market is saying about Immunovant’s

An AI-synthesized read of the highest-engagement posts about Immunovant’s on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunovant’s on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles